—A Webinar from Decision Resources
Based on our European Physician & Payer Forum report entitled Positioning of Current and Emerging Targeted Agents in Breast Cancer: Physician & Payer Perspective on Treatment and Reimbursement Decisions in Europe, Decision Resources is offering this exclusive webinar. Because this presentation will feature major findings, it is ONLY available to purchasers of this report.
Please contact us to learn how you can purchase this report and attend the webinar.
In 2010, the drug market for breast cancer in the EU5 (France, Germany, Italy, Spain and the United Kingdom) totalled nearly $4 billion with sales of Roche/Genentech/Chugai’s HER2-targeted monoclonal antibody (MAb) Herceptin (trastuzumab) accounting for more than one-third of the total market. Since its approval over a decade ago, Herceptin has faced limited competition from GlaxoSmithKline’s Tyverb (lapatinib), which has struggled to compete for share of the HER2-positive population. However, Herceptin’s dominance of the HER2-positive breast cancer market in Europe is threatened by the forecasted entry of biosimilar trastuzumab (beginning in 2014) and by the potential approval of competing HER2-targeted agents such as Pfizer’s neratinib. In order to maintain Herceptin’s overall HER2-positive breast cancer franchise, Roche, Genentech and Chugai have adopted a strong defensive strategy which includes the development of a subcutaneous formulation of Herceptin and the development of two second generation HER2-targeted agents; pertuzumab and Herceptin-DM1.
Roche/Genentech/Chugai’s VEGF MAb inhibitor Avastin (bevacizumab) has also enjoyed considerable commercial success since its approval for first-line metastatic breast cancer in Europe in 2007. However, in the wake of the FDA’s decision in December 2010 to begin the process of removing Avastin’s breast cancer label in the United States, Avastin’s foothold in the European breast cancer market has become increasingly vulnerable. Although still approved in Europe, sales of Avastin in this market have declined as a result of increased reimbursement restrictions throughout the EU5, and more discerning prescribing by oncologists.
Decision Resources surveyed 260 European oncologists and interviewed 15 payers in the EU5 to assess their attitudes and expectations surrounding current and emerging targeted therapies for breast cancer.
This webinar, presented by Decision Resources Analyst Niamh Buckley, Ph.D., will answer the following questions:
- How does the reimbursement and market access environment for breast cancer targeted therapies vary across the EU5 and in which EU5 markets do funding, reimbursement and/or budget restrictions pose the greatest barriers to patient access to targeted therapies?
- What cost control measures are employed to guide treatment, and how strictly is prescribing monitored by payers?
- What attributes have the most power to shift oncologists’ prescribing habits for breast cancer targeted therapies?
- How will the high cost of emerging targeted therapies, particularly emerging therapies that contain two targeted agents (notably Roche/Chugai’s pertuzumab in combination with Herceptin) affect market access and uptake?
- Do oncologists and payers consider subcutaneous delivery of Herceptin to be significantly advantageous over intravenous delivery and in what treatment settings (e.g. adjuvant or maintenance) are oncologists more likely to prescribe subcutaneous Herceptin?
- What are physicians’ and payers’ attitudes towards the entry of biosimilar versions of trastuzumab into the market and how will the entry of cheaper biosimilar versions of trastuzumab impact the uptake and reimbursement status of more expensive current and emerging branded agents?
- To what extent will the prescribing of novel breast cancer targeted therapies be affected by ongoing healthcare reforms and evolving cost-containment strategies in the EU5?
Webinar Details Date & Time Presentation: 30 minutes Q & A: 15 minutes |
About the Speaker
|
Niamh Buckley, Ph.D., is an oncology analyst at Decision Resources where she is an expert in breast cancer and ovarian cancer. Dr. Buckley obtained an honors degree in biotechnology and a Ph.D. on the molecular biology of cervical cancer from Trinity College in Ireland. She worked as a postdoctoral scientist for several years, during which time she was involved in a number of international translational breast cancer research projects. Most recently, she analyzed drug resistance and chromosomal instability in breast cancer. Dr. Buckley authored numerous peer-reviewed papers and abstracts and presented data at international cancer conferences.|
To learn how you can purchase this report and attend the webinar, please contact us using the information below. In North America In Europe In Japan |
Dr. Buckley will conduct a live Q & A session after the presentation.
Prescribing and Reimbursement of Targeted Therapies in Europe – How Will the Battle for Patient Share Evolve in the Lucrative Breast Cancer Drug Market?
December 9 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris).
Terms of Use | Privacy Policy | Contact Us | Careers
Decision Resources • 8 New England Executive Park • Burlington, MA 01803
You are receiving this email because you have previously requested information from Decision Resources. You can update your email preferences at any time.
© 2011 Decision Resources, LLC. All rights reserved.
